company background image
A278650 logo

HLB bioStepLtd KOSDAQ:A278650 Stock Report

Last Price

₩2.07k

Market Cap

₩174.3b

7D

-8.0%

1Y

-26.9%

Updated

13 Oct, 2024

Data

Company Financials

HLB bioStep Co.,Ltd.

KOSDAQ:A278650 Stock Report

Market Cap: ₩174.3b

A278650 Stock Overview

Provides various test services.

A278650 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

HLB bioStep Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HLB bioStepLtd
Historical stock prices
Current Share Price₩2,070.00
52 Week High₩4,705.00
52 Week Low₩2,010.00
Beta0.38
11 Month Change-14.81%
3 Month Change-25.14%
1 Year Change-26.86%
33 Year Change-24.88%
5 Year Changen/a
Change since IPO-48.96%

Recent News & Updates

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

Jul 17
Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

May 22
HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Mar 29
Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Recent updates

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

Jul 17
Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

May 22
HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Mar 29
Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden

Feb 28
Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden

With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting

Mar 17
With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting

What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?

Feb 24
What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?

Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?

Feb 03
Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?

Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%

Jan 13
Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%

Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?

Dec 23
Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?

Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?

Dec 02
Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?

Shareholder Returns

A278650KR Life SciencesKR Market
7D-8.0%3.9%0.9%
1Y-26.9%46.0%3.8%

Return vs Industry: A278650 underperformed the KR Life Sciences industry which returned 46% over the past year.

Return vs Market: A278650 underperformed the KR Market which returned 3.8% over the past year.

Price Volatility

Is A278650's price volatile compared to industry and market?
A278650 volatility
A278650 Average Weekly Movement5.4%
Life Sciences Industry Average Movement9.9%
Market Average Movement6.8%
10% most volatile stocks in KR Market12.2%
10% least volatile stocks in KR Market3.6%

Stable Share Price: A278650 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A278650's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012151In-Sung Jeonghlbbiostep.com

HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local infection model, PK study, chemical, transgenic animal, osteoblast-like cell line screening, bone formation marker, and biomarker.

HLB bioStep Co.,Ltd. Fundamentals Summary

How do HLB bioStepLtd's earnings and revenue compare to its market cap?
A278650 fundamental statistics
Market cap₩174.28b
Earnings (TTM)-₩6.15b
Revenue (TTM)₩49.17b

3.5x

P/S Ratio

-28.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A278650 income statement (TTM)
Revenue₩49.17b
Cost of Revenue₩16.26b
Gross Profit₩32.90b
Other Expenses₩39.05b
Earnings-₩6.15b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-73.01
Gross Margin66.92%
Net Profit Margin-12.50%
Debt/Equity Ratio28.5%

How did A278650 perform over the long term?

See historical performance and comparison